Close this search box.

Ozempic Lawsuit Legal Action Summary

Ozempic, a medication containing the active ingredient semaglutide, is endorsed by the U.S. FDA for managing type 2 diabetes through enhancing insulin output, thereby reducing blood glucose levels. It’s also recognized for its cardiovascular benefits and potential weight loss effects due to its once-weekly injection regimen.

The increasing adoption of Ozempic has brought to light concerns about its extended use potentially causing serious health issues related to the gallbladder and bile pathways. Our law firm is proactively examining claims related to Ozempic, especially for patients diagnosed with:

  • Gastric stasis
  • Non-functioning stomach
  • Blockage within the digestive system
  • Complete intestinal obstruction

Should you be diagnosed with any conditions listed above after Ozempic use, we urge you to get in touch for a no-cost assessment of your case.

Reach Out to Our Ozempic Lawsuit Attorneys Today

Timeline of Ozempic Legal Developments

  • February 21, 2024: Manufacturer’s Warning Failures Highlighted

    The lawsuit intensifies with allegations that Novo Nordisk failed to warn about Ozempic’s health risks adequately. Plaintiffs focus on proving the manufacturer’s knowledge of the drug’s side effects and their marketing practices.

  • February 16, 2024: First Status Conference Announcement

    A pivotal status conference is scheduled for March, aiming to discuss organizational matters, including lead counsel selection and procedural schedules, with potential expansion to include other drug manufacturers.

  • February 15, 2024: Injury Claims Focus

    As the lawsuit progresses, specific injuries linked to Ozempic use become central to strong cases, with gallbladder-related claims facing eligibility hurdles due to previous warnings by Novo Nordisk.

  • February 4, 2024: Establishment of Ozempic MDL

    MDL 3094 is officially formed, focusing on GLP-1 receptor agonists’ product liability, with proceedings set in the Eastern District of Pennsylvania, a venue known for plaintiff-friendly outcomes.

  • February 1, 2024: Anticipation of JPML Decision

    The Judicial Panel on Multi-District Litigation is expected to decide on the future scope of the lawsuit, considering whether to limit it to Ozempic or to include other similar medications.

  • January 25, 2024: Critical Decision Point

    The Judicial Panel on Multidistrict Litigation hears arguments on creating an MDL, signaling a likely consolidation without objection from the Ozempic manufacturer, with venue and inclusion of similar drugs by other manufacturers under deliberation.

  • January 20, 2024: Diverging Responses from Drug Manufacturers

    Novo Nordisk and Eli Lilly, makers of Ozempic and Mounjaro, respectively, show split stances on the consolidation proposal, with venue preferences indicating strategic legal positioning.

  • January 14, 2024: Proposal for a Unified MDL

    Attorneys propose consolidating Ozempic and similar drug-related lawsuits into a Multi-District Litigation (MDL) for efficiency and equity in the legal process, mirroring class action benefits but allowing for individual settlements.

  • January 7, 2024: Surge in Ozempic Lawsuits

    Following a JAMA study, lawsuits against Ozempic increase, emphasizing inadequate pre-release studies, insufficient warnings, and off-label usage concerns.

  • November 2023: Global Expansion of Legal Challenges

    Legal challenges extend beyond the U.S., with a Canadian law firm filing a suit in British Columbia over similar health risk warnings. Additionally, discussions emerge about a potential class action lawsuit by summer 2024, focusing on the drug’s severe gastrointestinal side effects.

  • October 2023: Research Highlights Gastrointestinal Risks

    A significant research letter in the Journal of the American Medical Association (JAMA) points out the increased risks of pancreatitis, gastroparesis, and intestinal obstruction from using GLP-1 agonist medications, including for off-label purposes like weight management.

  • August 2023: Initiation of Legal Actions

    The first legal claim is lodged against the producers of Ozempic and Wegovy, accusing them of not sufficiently alerting users about potential health dangers of these drugs. Both medications, classified as GLP-1 receptor agonists, are implicated in causing severe digestive system issues.

Understanding What Ozempic Is and How It Works

What is Ozempic?

Ozempic (semaglutide) is a prescription medication used for the treatment of type 2 diabetes. It belongs to a class of drugs known as GLP-1 receptor agonists, which work by mimicking the action of the naturally occurring hormone glucagon-like peptide-1 (GLP-1). GLP-1 is involved in the regulation of blood sugar levels. Specifically, Ozempic helps to:

  • Increase insulin release from the pancreas when blood sugar levels are high, which helps to lower blood sugar levels.
  • Decrease the amount of sugar produced by the liver.
  • Slow down food leaving the stomach, leading to a reduction in appetite and potentially assisting with weight loss.

Ozempic is administered via injection, typically once a week, and is used in conjunction with diet and exercise to improve blood sugar control in adults with type 2 diabetes. It’s important to note that it is not used for the treatment of type 1 diabetes or diabetic ketoacidosis. In some cases, it is also used off-label for weight management in individuals with or without diabetes, though its use for weight loss is officially approved under a different brand name for semaglutide, Wegovy.

How Does Ozempic Work?

Ozempic (semaglutide) works by mimicking the effects of the glucagon-like peptide-1 (GLP-1), a hormone that plays a crucial role in blood sugar regulation. GLP-1 is released into the bloodstream in response to food intake and has multiple actions that help lower blood glucose levels. By acting like GLP-1, Ozempic enhances the body’s natural ability to control blood sugar levels, making it an effective treatment for type 2 diabetes.

Firstly, Ozempic stimulates the pancreas to produce more insulin when blood sugar levels are high. Insulin is a hormone that helps cells in the body absorb glucose (sugar) from the bloodstream to use as energy or to store for future use, thus lowering blood sugar levels. Unlike some other diabetes medications, the insulin-release action of Ozempic is glucose-dependent, meaning it primarily stimulates insulin secretion when blood sugar levels are elevated, reducing the risk of hypoglycemia (abnormally low blood sugar levels).

Secondly, Ozempic reduces the amount of glucose produced by the liver. Normally, the liver releases glucose into the bloodstream to maintain energy supply between meals and during fasting periods. However, in people with type 2 diabetes, the liver can produce too much glucose, contributing to high blood sugar levels. Ozempic counters this by signaling the liver to reduce its glucose production, further aiding in blood sugar control.

Additionally, Ozempic slows gastric emptying, the process by which food exits the stomach and enters the small intestine. This action helps decrease appetite and can lead to a reduction in food intake and potentially weight loss. The slower movement of food through the gastrointestinal tract may also contribute to improved blood sugar levels after meals.

What are Common Side Effects of Ozempic?

Ozempic (semaglutide) can cause a range of side effects, some of which are more common than others. It’s important for individuals to be aware of these potential side effects so they can monitor their health and discuss any concerns with their healthcare provider. The most common side effects of Ozempic include:

  • Gastrointestinal issues: Many people experience gastrointestinal side effects when they start taking Ozempic. These can include nausea, vomiting, diarrhea, abdominal pain, and constipation. These symptoms are often most pronounced when beginning the medication and may decrease over time as the body adjusts to the drug.
  • Appetite changes: Ozempic can lead to a decrease in appetite, which is partly how it helps with weight loss in some individuals. While a reduced appetite can be beneficial for those looking to lose weight, it can sometimes lead to inadequate nutrient intake if not managed carefully.
  • Hypoglycemia: Although less common in medications like Ozempic that are glucose-dependent, there is still a risk of hypoglycemia (low blood sugar levels), especially when used in combination with other diabetes medications that increase insulin levels. Symptoms of hypoglycemia include dizziness, sweating, confusion, and shakiness.
  • Injection site reactions: As Ozempic is administered via injection, some people may experience reactions at the injection site, such as redness, itching, or pain. These reactions are usually mild and temporary.

Less common but more serious side effects can also occur with Ozempic. These include pancreatitis (inflammation of the pancreas), changes in vision, kidney problems, and an increased risk of thyroid cancer. It’s important to seek immediate medical attention if experiencing symptoms such as severe abdominal pain, persistent vomiting, vision changes, or signs of kidney issues like reduced urine output or swelling in the feet or ankles.

How Manufacturers Ozempic?

Novo Nordisk, a venerable healthcare firm from Denmark with over a century’s history since its founding in 1923, has been at the forefront of diabetes treatment, notably through insulin extraction. This long-standing company initially gained recognition with Victoza, a daily GLP-1 receptor agonist injection, before introducing Ozempic and Wegovy to the market.

The transition to these newer medications wasn’t without controversy. Novo Nordisk faced legal challenges, including a notable $1.1 million settlement related to allegations of off-label promotion of Victoza. Furthermore, the company settled for $58 million over claims it did not adhere to an FDA-required risk management program.

Currently, Novo Nordisk is navigating through legal waters once again with ongoing lawsuits concerning Ozempic and Wegovy. These lawsuits claim that the company did not adequately warn users about potential gallbladder-related risks associated with these medications, highlighting the ongoing scrutiny and challenges faced by pharmaceutical companies in ensuring patient safety and regulatory compliance.

Do You Have an Ozempic Lawsuit? Find Out Today!

Am I Eligible to File an Ozempic Lawsuit?

Criteria for Initiating an Ozempic Legal Claim Individuals who have developed negative health outcomes following the use of Ozempic, Rybelsus, or Wegovy, which are treatments involving GLP-1 receptor agonists, might be eligible for legal recourse.

To qualify for initiating a lawsuit related to Ozempic, the following conditions must be met:

  • Documentation confirming the administration of Ozempic, Rybelsus, or Wegovy;
  • A medical diagnosis indicating adverse health effects such as Gastroparesis, Stomach Paralysis, Ileus, or Gastrointestinal Obstruction during or within 30 days post-treatment. Legal professionals are also exploring potential claims linked to Pulmonary Embolism and Aspiration;
  • Documentation of a medical emergency or consultation with a Gastroenterologist owing to these conditions. It’s imperative to seek advice from a legal expert specializing in Ozempic cases to ascertain your eligibility and understand the implications of state-specific legal time limits.

How Do I File an Ozempic Lawsuit?

Should you suffer from conditions like Gastroparesis or similar health issues as a consequence of using Ozempic or Wegovy, you might be entitled to compensation. Consulting with a specialized lawyer in Ozempic cases is crucial to assess your case’s validity.

An expert Ozempic attorney can assist by:

  • Conducting a no-cost evaluation of your case to determine eligibility;
  • Gathering necessary evidence, including medical documents and testimonies, to bolster your claim;
  • Identifying and adhering to the legal deadlines specific to your state;
  • Managing negotiations for a settlement; and
  • Preparing for trial should settlement talks not yield a satisfactory outcome. Engaging a lawyer early in the process is beneficial. It’s important to provide your lawyer with comprehensive health records and any evidence pertinent to your case.

What are the Anticipated Settlement Amounts for the Ozempic Lawsuit?

The anticipated settlement in Ozempic litigation largely depends on the nature and extent of claimed damages. Given the variance in individual cases, a universal settlement amount doesn’t exist. However, cases involving gallbladder removal or wrongful death might see estimated settlements ranging between $400,000 and $700,000.

Compensation might cover:

  • Medical expenses;
  • Loss of earnings;
  • Pain and emotional distress;
  • Punitive damages.

Get In Touch with an Ozempic Lawyer to Discuss the Ozempic Lawsuit Today

If you have suffered any type of injuries as a result of using Ozempic, we strongly encourage you to get in touch with our Ozempic lawsuit attorneys today. We’re here and ready to help you get the compensation that you deserve.


Response time within minutes